Education
About Us
Working with TipRanks
Follow Us
Nanobiotix (NBTX)
NASDAQ:NBTX
NBTX Stock Chart & Stats
$23.60
-$0.03(-1.02%)
At close: 4:00 PM EST
$23.60
-$0.03(-1.02%)
Day’s Range― - ―
52-Week Range$2.76 - $30.23
Previous CloseN/A
Volume23.08K
Average Volume (3M)102.92K
Market Cap
$1.25B
Enterprise Value$250.61M
Total Cash (Recent Filing)$28.82M
Total Debt (Recent Filing)$51.24M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Nov 18, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding47,943,150
10 Day Avg. Volume175,893
30 Day Avg. Volume102,923
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)-1.99
Price to Sales (P/S)-11.28
P/FCF Ratio-6.42
Enterprise Value/Market Cap0.20
Enterprise Value/Revenue43.66
Enterprise Value/Gross Profit43.66
Enterprise Value/Ebitda-7.37
Forecast
1Y Price Target
$24.00Price Target Upside1.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Clinical ProgressThe first patient has been injected in an ongoing cohort study that adds standard-of-care chemotherapy to NBTXR3, indicating progress in research and development.
Financial StabilityA recent amendment of its licensing agreement with JNJ extends the company's cash runway to mid-2026, safeguarding the company's path through the interim analysis of the NANORAY-312 trial.
Partnership And CollaborationThe collaboration with JNJ and the totality of the NBTXR3 data are viewed as supportive with potential for large commercial opportunities.
Bears Say
Financial ConcernsInvestor focus is expected to remain on the company's cash runway and ongoing concerns about the balance sheet, implying financial stability is a key concern for stakeholders.
Investor UncertaintyInvestor focus will largely remain on the company's cash runway and the ongoing Phase III NANORAY-312 study in LA HNSCC.
Nanobiotix News
NBTX FAQ
What was Nanobiotix’s price range in the past 12 months?
Nanobiotix lowest stock price was $2.76 and its highest was $30.23 in the past 12 months.
What is Nanobiotix’s market cap?
Nanobiotix’s market cap is $1.25B.
When is Nanobiotix’s upcoming earnings report date?
Nanobiotix’s upcoming earnings report date is Nov 18, 2025 which is in 34 days.
How were Nanobiotix’s earnings last quarter?
Nanobiotix released its earnings results on Sep 30, 2025. The company reported -$0.129 earnings per share for the quarter, beating the consensus estimate of -$0.353 by $0.224.
Is Nanobiotix overvalued?
According to Wall Street analysts Nanobiotix’s price is currently Undervalued.
Does Nanobiotix pay dividends?
Nanobiotix does not currently pay dividends.
What is Nanobiotix’s EPS estimate?
Nanobiotix’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nanobiotix have?
Nanobiotix has 47,943,150 shares outstanding.
What happened to Nanobiotix’s price movement after its last earnings report?
Nanobiotix reported an EPS of -$0.129 in its last earnings report, beating expectations of -$0.353. Following the earnings report the stock price went down -0.794%.
Which hedge fund is a major shareholder of Nanobiotix?
Currently, no hedge funds are holding shares in NBTX
Nanobiotix Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$24.00 (1.69% Upside)
$24.00 (1.69% Upside)
Blogger Sentiment
Bullish
NBTX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 105.1K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
375.80%
12-Months-Change
Fundamentals
Return on Equity
2152.93%
Trailing 12-Months
Asset Growth
-42.92%
Trailing 12-Months
Company Description
Nanobiotix
Nanobiotix (NBTX) is a biotechnology company that specializes in the development of nanomedicine products to improve the efficacy of cancer treatments. Founded in 2003 and headquartered in Paris, France, the company focuses on leveraging its proprietary nanotechnology platform to enhance the efficacy of radiotherapy for the treatment of cancer. Nanobiotix's core product is NBTXR3, a first-in-class radioenhancer that is designed to improve the effectiveness of radiotherapy without increasing the dose delivered to surrounding healthy tissue.
NBTX Stock 12 Month Forecast
Average Price Target
$24.00
▲(1.69% Upside)
Technical Analysis
Mind Medicine
―
Bicara Therapeutics Inc.
―
Zenas BioPharma, Inc.
―
Upstream Bio, Inc.
―
Septerna, Inc.
―
Ownership Overview
―
Insiders
0.02% Mutual Funds
11.73% Other Institutional Investors
88.25% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---